Oncopeptides AB (LTS:0RN4) General and Admin. Expense: kr64.48 Mil (TTM As of Mar. 2026)


LTS:0RN4 Oncopeptides AB LTS:0RN4
46 GF Score
Price kr1.66
GF Value kr4.23
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB General and Admin. Expense?

Oncopeptides AB LTS:0RN4 -0.96% 46 General and Admin. Expense is kr64.48 Mil as of Mar. 2026. GuruFocus rates LTS:0RN4 with a GF Score™ of 46/100 and a GF Value™ of kr4.23 (Possible Value Trap). The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Oncopeptides AB's General and Admin. Expense for the three months ended in Mar. 2026 was kr13.19 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr64.48 Mil.

Oncopeptides AB General and Admin. Expense Related Terms

Oncopeptides AB General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB General and Admin. Expense Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 175.46 84.09 68.88 60.84 57.44

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.81 18.63 18.98 13.68 13.19
LTS:0RN4
46GF Score
Oncopeptides AB LTS:0RN4
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr64.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of kr64.48 Mil mean?
Oncopeptides AB (LTS:0RN4) has a General and Admin. Expense of kr64.48 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's General and Admin. Expense too high?
Oncopeptides AB's current General and Admin. Expense is kr64.48 Mil. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's General and Admin. Expense compare to VRTX and REGN?
Oncopeptides AB's General and Admin. Expense of kr64.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current General and Admin. Expense is kr64.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (LTS:0RN4) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.23, compared to a current price of kr1.66 — trading 60.8% below its estimated fair value. The current General and Admin. Expense is kr64.48 Mil. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Oncopeptides AB (LTS:0RN4), the current General and Admin. Expense is kr64.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.66 is trading 60.8% below its estimated GF Value™ of kr4.23. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for LTS:0RN4:

  • General and Admin. Expense: kr64.48 Mil
  • GF Value™: kr4.23 vs. price of kr1.66 (60.8% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score

Get the complete analysis for LTS:0RN4

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.66
Price
kr4.23
GF Value